Prystowsky E N, Heger J J, Chilson D A, Miles W M, Hubbard J, Zipes D P
Am J Cardiol. 1984 Nov 14;54(9):26D-28D. doi: 10.1016/s0002-9149(84)80282-9.
Twenty-six patients had ventricular tachycardia initiated at control electrophysiologic study and had a repeat study during oral propafenone therapy. Ten patients had had sustained ventricular tachycardia, 6 cardiac arrest and 10 symptomatic, nonsustained ventricular tachycardia. Twenty-two patients had heart disease, 18 of whom had coronary artery disease. During propafenone therapy, ventricular tachycardia could not be initiated during programmed ventricular stimulation in 5 patients, and in 21 patients the cycle length of induced ventricular tachycardia increased from 246 +/- 42 ms at control to 355 +/- 96 ms (p less than 0.001). Seventeen patients were discharged with propafenone therapy and have been followed for a mean of 11 months. No symptomatic ventricular tachycardia recurred in the 5 patients without inducible ventricular tachycardia during drug treatment. Six of 12 patients with inducible ventricular tachycardia during the drug study have remained asymptomatic. In conclusion, propafenone substantially prolongs the cycle length of ventricular tachycardia, and initiation of ventricular tachycardia by programmed ventricular stimulation at drug study does not preclude a favorable clinical outcome.
26例患者在对照电生理研究时诱发室性心动过速，并在口服普罗帕酮治疗期间进行了重复研究。10例患者曾发生持续性室性心动过速，6例发生心脏骤停，10例为有症状的非持续性室性心动过速。22例患者患有心脏病，其中18例患有冠状动脉疾病。在普罗帕酮治疗期间，5例患者在程控心室刺激时不能诱发室性心动过速，21例患者诱发室性心动过速的周长从对照时的246±42毫秒增加到355±96毫秒（P＜0.001）。17例患者接受普罗帕酮治疗出院，平均随访11个月。在药物治疗期间，5例不能诱发室性心动过速的患者未再发生有症状的室性心动过速。在药物研究期间可诱发室性心动过速的12例患者中，6例仍无症状。总之，普罗帕酮可显著延长室性心动过速的周长，且在药物研究中通过程控心室刺激诱发室性心动过速并不排除良好的临床结局。
